← Human Trials & Peer-Reviewed Studies
Antioxidative Efficacy of a Pistacia Lentiscus Supplement and Its Effect on the Plasma Amino Acid Profile in Inflammatory Bowel Disease: A Randomised, Double-Blind, Placebo-Controlled Trial.
Plain-language guide to PMID 30453494 (2018): double-blind randomized controlled trial of Copper (Supplement).
Key Facts
- PMID
- 30453494
- Journal
- Nutrients
- Year
- 2018
- Study type
- Randomized Controlled Trial
- Authors
- Papada E et al. (8 authors)
- DOI
- 10.3390/nu10111779
What This Study Did, in Plain Language
What Was Tested
Researchers studied Copper (Supplement) in this randomized controlled trial publication.
The objective of the present study was to assess the effects of a natural Pistacia lentiscus (PL) supplement on oxidative stress biomarkers and to characterise the plasma-free amino acid (AA) profiles of patients with active IBD (Crohn's disease (CD) N = 40, ulcerative colitis (UC) N = 20).
Why It Was Studied
The activity was determined according to 5 ≤ Harvey Bradshaw Index ≤ 16 or 2 ≤ Partial Mayo Score ≤ 6.
This is a randomised, double-blind, placebo-controlled clinical trial.
Who Took Part
The age groups tagged for this paper are teenagers, young adults, adults, middle-aged adults and older adults, both men and women.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
As a double-blind Copper (Supplement) study, the assignments were hidden from both participants and investigators until the end.
Some participants received a placebo instead of Copper (Supplement), giving a reference point.
Plasma oxidised, low-density lipoprotein (oxLDL), total serum oxidisability, and serum uric acid were evaluated at baseline and follow-up.
What Was Measured
The activity was determined according to 5 ≤ Harvey Bradshaw Index ≤ 16 or 2 ≤ Partial Mayo Score ≤ 6.
The subject headings attached to it are Amino Acids, Antioxidants, Biomarkers, Colitis, Ulcerative, Crohn Disease, Dietary Supplements and Inflammatory Bowel Diseases.
Author keywords: Crohn’s disease, oxidative stress, pistacia lentiscus (mastiha) and ulcerative colitis.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement).
The publication is from 2018 (Nutrients), a journal based in Switzerland.
More context: the Copper (Supplement) compound page, all human trials.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.